NASDAQ:VRDN - Viridian Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.00
  • Forecasted Upside: 110.90 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$17.07
▲ +0.5 (3.02%)

This chart shows the closing price for VRDN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Viridian Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRDN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRDN

Analyst Price Target is $36.00
▲ +110.90% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Viridian Therapeutics in the last 3 months. The average price target is $36.00, with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 110.90% upside from the last price of $17.07.

This chart shows the closing price for VRDN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Viridian Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/12/2021Evercore ISIInitiated CoverageOutperform$40.00Low
8/24/2021Lifesci CapitalReiterated RatingOutperformLow
1/25/2021LADENBURG THALM/SH SHInitiated CoverageBuy$40.00Low
1/20/2021Jefferies Financial GroupBoost Price TargetBuy$18.00 ➝ $28.00Low
(Data available from 10/18/2016 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/20/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/19/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2021
  • 3 very positive mentions
  • 25 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
10/18/2021

Current Sentiment

  • 3 very positive mentions
  • 25 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Viridian Therapeutics logo
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; and remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
Read More

Today's Range

Now: $17.07
Low: $16.20
High: $17.22

50 Day Range

MA: $14.00
Low: $10.69
High: $17.52

52 Week Range

Now: $17.07
Low: $7.08
High: $25.67

Volume

916 shs

Average Volume

104,642 shs

Market Capitalization

$163.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Viridian Therapeutics?

The following equities research analysts have issued research reports on Viridian Therapeutics in the last year: Evercore ISI, Jefferies Financial Group Inc., LADENBURG THALM/SH SH, Lifesci Capital, and Zacks Investment Research.
View the latest analyst ratings for VRDN.

What is the current price target for Viridian Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Viridian Therapeutics in the last year. Their average twelve-month price target is $36.00, suggesting a possible upside of 110.9%. LADENBURG THALM/SH SH has the highest price target set, predicting VRDN will reach $40.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $28.00 for Viridian Therapeutics in the next year.
View the latest price targets for VRDN.

What is the current consensus analyst rating for Viridian Therapeutics?

Viridian Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VRDN will outperform the market and that investors should add to their positions of Viridian Therapeutics.
View the latest ratings for VRDN.

What other companies compete with Viridian Therapeutics?

How do I contact Viridian Therapeutics' investor relations team?

Viridian Therapeutics' physical mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The company's listed phone number is (617) 272-4600 and its investor relations email address is [email protected] The official website for Viridian Therapeutics is www.viridiantherapeutics.com.